Faisal M Khan
Overview
Explore the profile of Faisal M Khan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ritwik P, Khan F
J Clin Ethics
. 2023 May;
34(2):211-217.
PMID: 37229734
AbstractPediatric dentists rely on access to hospital operating rooms for safe, effective, and humane delivery of dental care. The children who benefit most from dental treatment in a hospital operating...
2.
Tripathi G, Khanolkar R, Faridi R, Kalra A, Dharmani-Khan P, Shabani-Rad M, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555525
The persistence of graft-versus-host disease (GVHD) as the principal complication of allogeneic hematopoietic cell transplantation (HCT) demonstrates that HLA matching alone is insufficient to prevent alloreactivity. We performed molecular and...
3.
Khanolkar R, Tripathi G, Dharmani-Khan P, Dabas R, Kinzel M, Kalra A, et al.
Cytotherapy
. 2022 Sep;
24(12):1225-1231.
PMID: 36057497
Background Aims: The value of routine chimerism determination after myeloablative hematopoietic cell transplantation (HCT) is unclear, particularly in the setting of anti-thymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis. Methods: Blood...
4.
Lee C, Lin J, Prokop A, Gopalakrishnan V, Hanna R, Papa E, et al.
Front Genet
. 2022 Jun;
13:868015.
PMID: 35711912
Target prioritization is essential for drug discovery and repositioning. Applying computational methods to analyze and process multi-omics data to find new drug targets is a practical approach for achieving this....
5.
Luu L, Pillai A, Lea H, Buendia R, Khan F, Dennis G
Sensors (Basel)
. 2022 Jun;
22(11).
PMID: 35684609
Physical activity (PA) is globally recognized as a pillar of general health. Step count, as one measure of PA, is a well known predictor of long-term morbidity and mortality. Despite...
6.
Shameer K, Zhang Y, Prokop A, Nampally S, N I, Weatherall J, et al.
JCO Clin Cancer Inform
. 2022 Apr;
6:e2100173.
PMID: 35467964
Purpose: Overall survival (OS) is the gold standard end point for establishing clinical benefits in phase III oncology trials. However, these trials are associated with low success rates, largely driven...
7.
Buendia R, Havsol J, Lundberg V, Sooben K, Jornten-Karlsson M, Nyman E, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2021 Dec;
2021:1372-1375.
PMID: 34891540
Management of type 2 diabetes mellitus (T2DM) is a serious medical need for millions of patients and clinicians worldwide. Numerous smartphone apps for T2DM management are available. Due to their...
8.
Khanolkar R, Faridi R, Kinzel M, Jamani K, Savoie M, Shafey M, et al.
Cytotherapy
. 2021 Dec;
24(4):413-420.
PMID: 34863627
Background Aims: The internal tandem duplication of FLT3 (FLT3) and NPM1 mutations (NPM1) are well-established prognostic factors in cytogenetically intermediate-risk acute myeloid leukemia (AML) when treated with chemotherapy alone. However,...
9.
Storek J, Kanji J, Choi M, Kalra A, Chaudhry A, Jamani K, et al.
Bone Marrow Transplant
. 2021 Oct;
57(1):119-121.
PMID: 34616007
No abstract available.
10.
Shameer K, Zhang Y, Jackson D, Rhodes K, Neelufer I, Nampally S, et al.
Front Oncol
. 2021 Aug;
11:672916.
PMID: 34381708
Early endpoints, such as progression-free survival (PFS), are increasingly used as surrogates for overall survival (OS) to accelerate approval of novel oncology agents. Compiling trial-level data from randomized controlled trials...